{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:25:35Z","timestamp":1770751535352,"version":"3.50.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,12,26]],"date-time":"2004-12-26T00:00:00Z","timestamp":1104019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,12,26]],"date-time":"2004-12-26T00:00:00Z","timestamp":1104019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2005,1,1]]},"DOI":"10.1038\/nm1160","type":"journal-article","created":{"date-parts":[[2004,12,26]],"date-time":"2004-12-26T22:17:14Z","timestamp":1104099434000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":431,"title":["Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway"],"prefix":"10.1038","volume":"11","author":[{"given":"Alessandra","family":"Insinga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Monestiroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Ronzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vania","family":"Gelmetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Nervi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giuseppe","family":"Pelicci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,12,26]]},"reference":[{"key":"BFnm1160_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194\u2013202 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm1160_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"RW Johnstone","year":"2002","unstructured":"Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287\u2013299 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnm1160_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone, R.W. & Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13\u201318 (2003).","journal-title":"Cancer Cell"},{"key":"BFnm1160_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1517\/13543784.11.12.1695","volume":"11","author":"WK Kelly","year":"2002","unstructured":"Kelly, W.K., O'Connor, O.A. & Marks, P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 11, 1695\u20131713 (2002).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnm1160_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","volume":"92","author":"PA Marks","year":"2000","unstructured":"Marks, P.A., Richon, V.M. & Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210\u20131216 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnm1160_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","volume":"391","author":"F Grignani","year":"1998","unstructured":"Grignani, F. et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815\u2013818 (1998).","journal-title":"Nature"},{"key":"BFnm1160_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1097-2765(00)80321-4","volume":"5","author":"S Minucci","year":"2000","unstructured":"Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811\u2013820 (2000).","journal-title":"Mol. Cell"},{"key":"BFnm1160_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1097-2765(00)80322-6","volume":"5","author":"RJ Lin","year":"2000","unstructured":"Lin, R.J. & Evans, R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821\u2013830 (2000).","journal-title":"Mol. Cell"},{"key":"BFnm1160_CR9","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1182\/blood-2001-11-0089","volume":"100","author":"S Minucci","year":"2002","unstructured":"Minucci, S. et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100, 2989\u20132995 (2002).","journal-title":"Blood"},{"key":"BFnm1160_CR10","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","volume":"93","author":"A Melnick","year":"1999","unstructured":"Melnick, A. & Licht, J.D. Deconstructing a disease: RAR\u03b1, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167\u20133215 (1999).","journal-title":"Blood"},{"key":"BFnm1160_CR11","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood.V93.7.2143","volume":"93","author":"P Westervelt","year":"1999","unstructured":"Westervelt, P. & Ley, T.J. Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood 93, 2143\u20132148 (1999).","journal-title":"Blood"},{"key":"BFnm1160_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0092-8674(93)80044-F","volume":"74","author":"F Grignani","year":"1993","unstructured":"Grignani, F. et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74, 423\u2013431 (1993).","journal-title":"Cell"},{"key":"BFnm1160_CR13","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1128\/MCB.17.8.4859","volume":"17","author":"M Ruthardt","year":"1997","unstructured":"Ruthardt, M. et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor \u03b1 (RAR \u03b1) and PLZF-RAR \u03b1 fusion proteins on retinoic acid signalling. Mol. Cell. Biol. 17, 4859\u20134869 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm1160_CR14","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1038\/sj.onc.1202630","volume":"18","author":"T Casini","year":"1999","unstructured":"Casini, T. & Pelicci, P.G. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 18, 3235\u20133243 (1999).","journal-title":"Oncogene"},{"key":"BFnm1160_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.1065173","volume":"295","author":"L Di Croce","year":"2002","unstructured":"Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079\u20131082 (2002).","journal-title":"Science"},{"key":"BFnm1160_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.emboj.7600109","volume":"23","author":"A Insinga","year":"2004","unstructured":"Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144\u20131154 (2004).","journal-title":"EMBO J."},{"key":"BFnm1160_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1006\/excr.2000.4840","volume":"256","author":"H Walczak","year":"2000","unstructured":"Walczak, H. & Krammer, P.H. The CD95 (APO-1\/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58\u201366 (2000).","journal-title":"Exp. Cell Res."},{"key":"BFnm1160_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrc821","volume":"2","author":"A Ashkenazi","year":"2002","unstructured":"Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420\u2013430 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm1160_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","volume":"10","author":"HN LeBlanc","year":"2003","unstructured":"LeBlanc, H.N. & Ashkenazi, A. Apo2L\/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66\u201375 (2003).","journal-title":"Cell Death Differ."},{"key":"BFnm1160_CR20","first-page":"2","volume":"61","author":"FF Ferrara","year":"2001","unstructured":"Ferrara, F.F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2\u20137 (2001).","journal-title":"Cancer Res."},{"key":"BFnm1160_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone, R.W., Ruefli, A.A. & Lowe, S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153\u2013164 (2002).","journal-title":"Cell"},{"key":"BFnm1160_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2002-12-3779","volume":"102","author":"P Westervelt","year":"2003","unstructured":"Westervelt, P. et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RAR\u03b1 expression. Blood 102, 1857\u20131865 (2003).","journal-title":"Blood"},{"key":"BFnm1160_CR23","doi-asserted-by":"publisher","first-page":"10398","DOI":"10.1073\/pnas.171321298","volume":"98","author":"Y Yuan","year":"2001","unstructured":"Yuan, Y. et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Nat.l Acad. Sci. USA 98, 10398\u201310403 (2001).","journal-title":"Proc. Nat.l Acad. Sci. USA"},{"key":"BFnm1160_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1535-6108(02)00016-8","volume":"1","author":"M Higuchi","year":"2002","unstructured":"Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 63\u201374 (2002).","journal-title":"Cancer Cell"},{"key":"BFnm1160_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm828","volume":"9","author":"E Song","year":"2003","unstructured":"Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347\u2013351 (2003).","journal-title":"Nat. Med."}],"updated-by":[{"DOI":"10.1038\/nm0205-233a","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:11:58Z","timestamp":1684447918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"alternative-id":["BFnm1160"],"URL":"https:\/\/doi.org\/10.1038\/nm1160","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nm0205-233a","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,26]]},"assertion":[{"value":"6 July 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}